Recently, immunocheckpoint inhibitors, such as anti-PD-1/anti-PD-L1 antibodies, were used in a clinical setting for several cancers [14,15,16], and a few basic studies reported the synergistic effects of PDT and immunocheckpoint inhibitors [17,18]. The gene discussed is CD274; the disease is cancer.